4 clinics coming soon: Murray, Draper, Salt Lake City, Park City (July-Sept.4 clinics in operation: Springville, Orem, Draper and Layton.Transcranial Magnetic Stimulation therapy, a non-invasive FDA-approved treatment that uses magnetic fields to stimulate areas of the brain affiliated with depression.SpravatoTM, an FDA-approved nasal spray version of ketamine for treatment-resistant depression and major depressive disorder with suicidal ideation or behaviour, over 2,800 treatments administered.Ketamine-assisted therapy, the “ first legal psychedelic” over 7,000 treatments administered.Forecasted to increase patient volume from 20,000 client visits recorded in 2020 to approximately 65,000 client visits in 2021, +225% YoY.$1.3M in fiscal Q2 revenue from four mental health clinics.Facilitated over 20,000 client visits in 2020, an increase of over 100% compared to the same period in 2019.Providing access to innovative, evidence based mental healthcare since 2016.One of America’s leading providers of psychedelic medicine $1.29 million in fiscal second quarter revenue.Biopharma partnerships with Johnson & Johnson ( Janssen Spravato trials ) and Merck for New Treatment-Resistant Depression Trial.Building centers of excellence for future approved psychedelic treatments.Specializing in psychedelic-assisted treatment protocols.Positioned to facilitate MDMA and psilocybin therapy post-FDA approval.During the same period, total Spravato™ treatments rose 400%.Ketamine treatment volume grew 90% from 2019 to 2020.Provides ketamine-assisted psychotherapy and Spravato™ (esketamine) treatments.Rapidly expanding a network of outpatient mental health clinics and research sites.Building the infrastructure required for a regulated psychedelics industry.Phase II study will assess the efficacy and safety of a new Merck drug for treatment-resistant depression (TRD), a mental health condition that affects approximately 30% of people who suffer from major depressive disorder.Wholly-owned subsidiary, Cedar Clinical Research selected as a key research site for a clinical trial focused on treatment-resistant depression by Merck & Co.Novamind Partners with Merck for New Treatment-Resistant Depression Trial Replicating the successful operating track record of its current clinics in Utah, at scale, ahead of its expansion into other American states in 2021.New Clinics represent the initial phase of Novamind's national expansion strategy.Construction has begun on three of the New Clinics and leased a fourth additional property.20,000 client visits recorded in 2020 to approximately 65,000 client visitsanticipated in 2021.Capacity from the New Clinics is forecasted to increase Novamind's patient volume from:.Doubling its network to eight total locations. BREAKING: Novamind Doubles in Size, Adds Four New Psychedelic Mental Health Clinics
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |